5-amino-1mq human study safety Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice 5-Amino-1MQ Peptide - 50mg

Body-weight changes do not reveal long-term safety

However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007

Decrease dose if: Experiencing consistent side effects (headaches, fatigue, GI disturbance), achieving satisfactory results at current dose with no need for escalation, or cost considerations favor using minimum effective dose

Zhang J, Wang Y, Li G, Yu H, Xie X (2014) Down-Regulation of Nicotinamide N -methyltransferase Induces Apoptosis in Human Breast Cancer Cells via the Mitochondria-Mediated Pathway

Arthur Heller, HealthTap There is also the risk of bacterial contamination, which increases as the B12 ages